File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma

TitleA systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
Authors
KeywordsNasopharyngeal carcinoma
Plasma EBV DNA
Clinical application
Levels of evidence
Recommendation
Issue Date2021
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca
Citation
European Journal of Cancer, 2021, v. 153, p. 109-122 How to Cite?
AbstractIntroduction: Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeast Asia, particularly Southern China. The classical non-keratinising cell type is almost unanimously associated with latent Epstein–Barr virus (EBV) infection. Circulating plasma EBV DNA can be a useful biomarker in various clinical aspects, but comprehensive recommendations and international guidelines are still lacking. We conducted a systematic review of all original articles on the clinical application of plasma EBV DNA for NPC; we further evaluated its strengths and limitations for consideration as standard recommendations. Methods: The search terms ‘nasopharyngeal OR nasopharynx’, and ‘plasma EBV DNA OR cell-free EBV OR cfEBV’ were used to identify full-length articles published up to December 2020 in the English literature. Three authors independently reviewed the article titles, removed duplicates and reviewed the remaining articles for eligibility. Results: A total of 81 articles met the eligibility criteria. Based on the levels of evidence and grades of recommendation assessed, it is worth considering the inclusion of plasma EBV DNA in screening, pre-treatment work-up for enhancing prognostication and tailoring of treatment strategy, monitoring during radical treatment, post-treatment surveillance for early detection of relapse, and monitoring during salvage treatment for recurrent or metastatic NPC. One major limitation is the methodology of measurement requiring harmonisation for consistent comparability. Conclusions: The current comprehensive review supports the inclusion of plasma EBV DNA in international guidelines in the clinical aspects listed, but methodological issues must be resolved before global application.
Persistent Identifierhttp://hdl.handle.net/10722/300781
ISSN
2020 Impact Factor: 9.162
2015 SCImago Journal Rankings: 3.152

 

DC FieldValueLanguage
dc.contributor.authorLee, AWM-
dc.contributor.authorLee, VHF-
dc.contributor.authorNg, WT-
dc.contributor.authorStrojan, P-
dc.contributor.authorSaba, NF-
dc.contributor.authorRinaldo, A-
dc.contributor.authorWillems, SM-
dc.contributor.authorRodrigo, JP-
dc.contributor.authorForastiere, AA-
dc.contributor.authorFerlito, A-
dc.date.accessioned2021-07-06T03:10:09Z-
dc.date.available2021-07-06T03:10:09Z-
dc.date.issued2021-
dc.identifier.citationEuropean Journal of Cancer, 2021, v. 153, p. 109-122-
dc.identifier.issn0959-8049-
dc.identifier.urihttp://hdl.handle.net/10722/300781-
dc.description.abstractIntroduction: Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeast Asia, particularly Southern China. The classical non-keratinising cell type is almost unanimously associated with latent Epstein–Barr virus (EBV) infection. Circulating plasma EBV DNA can be a useful biomarker in various clinical aspects, but comprehensive recommendations and international guidelines are still lacking. We conducted a systematic review of all original articles on the clinical application of plasma EBV DNA for NPC; we further evaluated its strengths and limitations for consideration as standard recommendations. Methods: The search terms ‘nasopharyngeal OR nasopharynx’, and ‘plasma EBV DNA OR cell-free EBV OR cfEBV’ were used to identify full-length articles published up to December 2020 in the English literature. Three authors independently reviewed the article titles, removed duplicates and reviewed the remaining articles for eligibility. Results: A total of 81 articles met the eligibility criteria. Based on the levels of evidence and grades of recommendation assessed, it is worth considering the inclusion of plasma EBV DNA in screening, pre-treatment work-up for enhancing prognostication and tailoring of treatment strategy, monitoring during radical treatment, post-treatment surveillance for early detection of relapse, and monitoring during salvage treatment for recurrent or metastatic NPC. One major limitation is the methodology of measurement requiring harmonisation for consistent comparability. Conclusions: The current comprehensive review supports the inclusion of plasma EBV DNA in international guidelines in the clinical aspects listed, but methodological issues must be resolved before global application.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca-
dc.relation.ispartofEuropean Journal of Cancer-
dc.subjectNasopharyngeal carcinoma-
dc.subjectPlasma EBV DNA-
dc.subjectClinical application-
dc.subjectLevels of evidence-
dc.subjectRecommendation-
dc.titleA systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma-
dc.typeArticle-
dc.identifier.emailLee, AWM: awmlee@hkucc.hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailNg, WT: ngwt1@hkucc.hku.hk-
dc.identifier.authorityLee, AWM=rp02056-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityNg, WT=rp02671-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ejca.2021.05.022-
dc.identifier.scopuseid_2-s2.0-85109030211-
dc.identifier.hkuros323330-
dc.identifier.volume153-
dc.identifier.spage109-
dc.identifier.epage122-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats